[Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment].
Currently available data and clinical observations which suggest that there is a pathogenetic relationship between hypertension, diabetes mellitus, and atherosclerosis have provided a concept of the X syndrome, by which hypertensive patients, mainly males, have impaired insulin tolerance along with hyperinsulinemia and concurrent atherogenic disorders of lipid metabolism. The paper discussed the specific pathogenetic mechanisms, clinical manifestations, and prospects for drug correction of the metabolic syndrome. The treatment of arterial hypertension with the calcium antagonist Lomir has indicated there are no negative changes as a control of non-insulin-dependent diabetes mellitus in the presence of effective correction of arterial hypertension and atherogenic dyslipidemias. With the monotherapy of essential hypertension concurrent with hypercholesterolemia with the alpha 1-adrenoblocker Doxazosin, in addition to the agent's high antihypertensive effects, the authors noted its favourable action on lipid spectral parameters and platelet functional activity. There is abundant evidence for the use of specific hypolipidemic agents in patients with essential hypertensive refractory to current antihypertensive drugs. The data obtained with the use of Lescol (fluvastatin) in patients with hypertensive disease and hypercholesterolemia suggest that by substantially reducing the levels of total cholesterol, triglycerides, low density lipoprotein cholesterol and its transport protein apo B does not deteriorate the quality of correction of arterial hypertension in this group of patients.
Moiseev
V S
VS
Ivleva
A Ia
AIa
Kobalava
Zh D
ZhD
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000209:etiology*; D003920:Diabetes Mellitus / Q000209:etiology*; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism; D017292:Doxazosin / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use; D005260:Female; D000077340:Fluvastatin; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D006937:Hypercholesterolemia / Q000188:drug therapy; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology*; D007211:Indoles / Q000627:therapeutic use; D007333:Insulin Resistance; D017275:Isradipine / Q000627:therapeutic use; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D013577:Syndrome
D000924:Anticholesteremic Agents; D004791:Enzyme Inhibitors; D005229:Fatty Acids, Monounsaturated; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D000077340:Fluvastatin; D017292:Doxazosin; D017275:Isradipine
Gipertoniia, sakharnyĭ diabet, ateroskleroz--klinicheskie proiavleniia metabolicheskogo sindroma X. Perspektivy farmakologicheskoĭ korrektsii.